Intellipharmaceutics International Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IPCI.TO research report →
Companywww.intellipharmaceutics.com
Intellipharmaceutics International Inc. , a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain.
- CEO
- Isa Odidi MBA,
- IPO
- 1999
- Employees
- 11
- HQ
- Toronto, ON, CA
Price Chart
Valuation
- Market Cap
- $2.65M
- P/E
- -1.72
- P/S
- 75.52
- P/B
- -0.47
- EV/EBITDA
- -2.73
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 100.00%
- Op Margin
- -4336.82%
- Net Margin
- -4400.55%
- ROE
- 27.35%
- ROIC
- 34.55%
Growth & Income
- Revenue
- $65.73K · 0.00%
- Net Income
- $-2,892,394 · 43.78%
- EPS
- $-0.09 · 48.59%
- Op Income
- $-2,850,507
- FCF YoY
- 43.60%
Performance & Tape
- 52W High
- $0.17
- 52W Low
- $0.04
- 50D MA
- $0.08
- 200D MA
- $0.09
- Beta
- 0.29
- Avg Volume
- 4.91K
Get TickerSpark's AI analysis on IPCI.TO
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our IPCI.TO Coverage
We haven't published any research on IPCI.TO yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate IPCI.TO Report →